Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Research & Development (2016 - 2025)

Sangamo Therapeutics has reported Research & Development over the past 16 years, most recently at $31.4 million for Q4 2025.

  • Quarterly results put Research & Development at $31.4 million for Q4 2025, up 32.79% from a year ago — trailing twelve months through Dec 2025 was $112.7 million (up 1.03% YoY), and the annual figure for FY2025 was $112.7 million, up 1.03%.
  • Research & Development for Q4 2025 was $31.4 million at Sangamo Therapeutics, up from $28.1 million in the prior quarter.
  • Over the last five years, Research & Development for SGMO hit a ceiling of $66.2 million in Q4 2022 and a floor of $23.7 million in Q4 2024.
  • Median Research & Development over the past 5 years was $54.1 million (2021), compared with a mean of $46.9 million.
  • Biggest five-year swings in Research & Development: surged 44.71% in 2021 and later plummeted 61.58% in 2024.
  • Sangamo Therapeutics' Research & Development stood at $51.8 million in 2021, then increased by 27.76% to $66.2 million in 2022, then fell by 23.38% to $50.7 million in 2023, then crashed by 53.31% to $23.7 million in 2024, then surged by 32.79% to $31.4 million in 2025.
  • The last three reported values for Research & Development were $31.4 million (Q4 2025), $28.1 million (Q3 2025), and $27.1 million (Q2 2025) per Business Quant data.